» Articles » PMID: 23056502

Identifying MRNA, MicroRNA and Protein Profiles of Melanoma Exosomes

Overview
Journal PLoS One
Date 2012 Oct 12
PMID 23056502
Citations 149
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Exosomes are small membranous vesicles secreted into body fluids by multiple cell types, including tumor cells, and in various disease conditions. Tumor exosomes contain intact and functional mRNAs, small RNAs (including miRNAs), and proteins that can alter the cellular environment to favor tumor growth. Molecular profiling may increase our understanding of the role of exosomes in melanoma progression and may lead to discovery of useful biomarkers.

Methodology/principal Findings: In the present study, we used mRNA array profiling to identify thousands of exosomal mRNAs associated with melanoma progression and metastasis. Similarly, miRNA array profiling identified specific miRNAs, such as hsa-miR-31, -185, and -34b, involved in melanoma invasion. We also used proteomic analysis and discovered differentially expressed melanoma exosomal proteins, including HAPLN1, GRP78, syntenin-1, annexin A1, and annexin A2. Importantly, normal melanocytes acquired invasion ability through molecules transported in melanoma cell-derived exosomes.

Conclusions/significance: Our results indicate that melanoma-derived exosomes have unique gene expression signatures, miRNA and proteomics profiles compared to exosomes from normal melanocytes. To the best of our knowledge, this is the first in-depth screening of the whole transcriptome/miRNome/proteome expression in melanoma exosomes. These results provide a starting point for future more in-depth studies of tumor-derived melanoma exosomes, which will aid our understanding of melanoma biogenesis and new drug-targets that may be translated into clinical applications, or as non-invasive biomarkers for melanoma.

Citing Articles

Extracellular vesicles derived from melanoma cells induce carcinoma-associated fibroblasts via miR-92b-3p mediated downregulation of PTEN.

Kewitz-Hempel S, Windisch N, Hause G, Muller L, Sunderkotter C, Gerloff D J Extracell Vesicles. 2024; 13(9):e12509.

PMID: 39315679 PMC: 11420832. DOI: 10.1002/jev2.12509.


Exosome Mediated Cell-Cell Crosstalk in Tissue Injury and Repair.

Yadav A, Nandy A, Sharma A, Ghatak S Results Probl Cell Differ. 2024; 73:249-297.

PMID: 39242383 DOI: 10.1007/978-3-031-62036-2_12.


Liquid biopsy for diagnostic and prognostic evaluation of melanoma.

Slusher N, Jones N, Nonaka T Front Cell Dev Biol. 2024; 12:1420360.

PMID: 39156972 PMC: 11327088. DOI: 10.3389/fcell.2024.1420360.


Melanocytes in regenerative medicine applications and disease modeling.

Coutant K, Magne B, Ferland K, Fuentes-Rodriguez A, Chancy O, Mitchell A J Transl Med. 2024; 22(1):336.

PMID: 38589876 PMC: 11003097. DOI: 10.1186/s12967-024-05113-x.


Stem Cell-Derived Extracellular Vesicles in the Treatment of Cardiovascular Diseases.

McDonald J, Mohak S, Fabian Z Pharmaceutics. 2024; 16(3).

PMID: 38543275 PMC: 10974254. DOI: 10.3390/pharmaceutics16030381.


References
1.
Lokman N, Ween M, Oehler M, Ricciardelli C . The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenviron. 2011; 4(2):199-208. PMC: 3170418. DOI: 10.1007/s12307-011-0064-9. View

2.
Choi H, Ahn S, Chang H, Cho N, Joo K, Lee B . Influence of N-glycan processing disruption on tyrosinase and melanin synthesis in HM3KO melanoma cells. Exp Dermatol. 2007; 16(2):110-7. DOI: 10.1111/j.1600-0625.2006.00515.x. View

3.
Ogura T, Noguchi T, Murai-Takebe R, Hosooka T, Honma N, Kasuga M . Resistance of B16 melanoma cells to CD47-induced negative regulation of motility as a result of aberrant N-glycosylation of SHPS-1. J Biol Chem. 2004; 279(14):13711-20. DOI: 10.1074/jbc.M310276200. View

4.
Grewal T, Enrich C . Annexins--modulators of EGF receptor signalling and trafficking. Cell Signal. 2009; 21(6):847-58. DOI: 10.1016/j.cellsig.2009.01.031. View

5.
Sandhu S, Garzon R . Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment. Semin Oncol. 2011; 38(6):781-7. DOI: 10.1053/j.seminoncol.2011.08.007. View